Pharmacogenetics of Nevirapine-Associated Hepatotoxicity: An Adult AIDS Clinical Trials Group Collaboration
Open Access
- 15 September 2006
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 43 (6) , 783-786
- https://doi.org/10.1086/507097
Abstract
Associations have been reported between an MDR1 variant and responses to nonnucleoside reverse-transcriptase inhibitors. We explored associations betKeywords
This publication has 10 references indexed in Scilit:
- Pharmacogenetics of Long‐Term Responses to Antiretroviral Regimens Containing Efavirenz and/or Nelfinavir: An Adult AIDS Clinical Trials Group StudyThe Journal of Infectious Diseases, 2005
- Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stabilityPharmacogenetics and Genomics, 2005
- Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivoPharmacogenetics and Genomics, 2005
- Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individualsClinical Pharmacology & Therapeutics, 2005
- Severe Hepatotoxicity Associated with Nevirapine Use in HIV‐Infected SubjectsThe Journal of Infectious Diseases, 2005
- Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell countsAIDS, 2005
- Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patientsPharmacogenetics and Genomics, 2005
- Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevanceClinical Pharmacology & Therapeutics, 2004
- Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture.Pharmaceutical Research, 2002
- Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics studyThe Lancet, 2002